Interstitial Cystitis Market
The total diagnosed prevalent population of Interstitial Cystitis in the 7MM was 2,264,118 in 2017. The diagnosed prevalent cases of Interstitial Cystitis in the United States were found to be 1,459,502 in 2017. It is observed that womens are more affected with IC as compared to males. The market size of Interstitial Cystitis in the 7MM was USD 1,599 Million in 2017, which is expected to increase during the forecast period 2017-2030. FDA approved oral medication, increasing emerging therapies, increasing awareness are some of the key factors expected to drive the IC market in the coming years. The key companies in the therapeutics market of Interstitial Cystitis includes KYORIN Pharmaceutical, UCB, Gru00fcnenthal, Astellas Pharma, Lipella Pharmaceuticals, SEIKAGAKU CORPORATION and many others. For more information visit: https://www.delveinsight.com/report-store/interstitial-cystitis-market
52 views • 1 slides